NCT01105429View on ClinicalTrials.gov

Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
DRUG

BMS-820132

Oral Solution, Oral, 0.3 mg, once daily, 1 day

DRUG

BMS-820132

Oral Solution, Oral, 1.0 mg, once daily, 1 day

DRUG

BMS-820132

Oral Solution, Oral, 3 mg, once daily, 1 day

DRUG

BMS-820132

Oral Solution, Oral, 10 mg, once daily, 1 day

DRUG

BMS-820132

Oral Solution, Oral, 30 mg, once daily, 1 day

DRUG

BMS-820132

Oral Solution, Oral , 75 mg, once daily, 1 day

DRUG

BMS-820132

Oral Solution, Oral, 150 mg, once daily, 1 day

DRUG

BMS-820132

Oral Solution, Oral, 300 mg, once daily, 1 day

DRUG

BMS-820132

Capsule, Oral, (TBD), once daily, 2 days

DRUG

Placebo

Oral Solution, Oral, 0mg, once daily, 1 day

DRUG

Placebo

Capsule, Oral, (TBD), once daily, 2 days

Trial Locations (3)

33014

Clinical Pharmacology Of Miami Inc., Miami

33169

Elite Research Institute, Miami

91911

Profil Institute For Clinical Research, Inc. (Picr), Chula Vista

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY